What Respira-D Treats: Main Uses and Benefits

Respira-D is a combination medication commonly used to provide symptomatic relief for the concurrent symptoms of the common cold and allergies. The medication is considered relevant in contexts involving heightened systemic burden, offering supportive relief that helps patients cope more steadily with symptom fluctuations.

This therapeutic combination is relevant across domains where short-term symptomatic assistance is appropriate. It is commonly applied in addressing conditions associated with acute or disruptive episodes, such as: common cold symptoms, seasonal allergic rhinitis, and non-productive cough.

The medicine is relevant for managing symptoms that interfere with daily comfort, and may contribute to improved comfort during periods of heightened symptoms.

“The combined support may assist with managing simultaneous allergic and cough manifestations, supporting patients' day-to-day comfort when symptoms are more noticeable.”

---

Symptomatic Focus Respira-D is typically used when patients require an integrated approach to manage both allergic symptoms (like sneezing and runny nose) and a dry cough concurrently.

Regulatory References

1. DailyMed overview from the National Library of Medicine

Eligibility Map: Who can and Cannot Use Respira-D — Official Regulatory Information

The eligibility profile for Respira-D (a combination of a cough suppressant and an antihistamine) is strictly defined by government regulatory documents to ensure patient safety. Eligibility status is determined by age, pre-existing health conditions, and current medication use.

---

Populations for Whom Use is Contraindicated

Use of this medicine is prohibited under the following circumstances, which represent absolute exclusions:

• Hypersensitivity: Known allergy to chlorpheniramine, dextromethorphan, or any other component.
• MAOI Use: Patients who are taking or have taken a Monoamine Oxidase Inhibitor (MAOI), or similar-acting medications (e.g., phenelzine, linezolid), within the last 14 days.
• Specific Conditions: Patients with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, or urinary retention.
• Children: Generally contraindicated in children below 2 years of age.

---

Populations Requiring Restricted or Conditional Use

Consultation with a healthcare provider is mandatory before use for individuals with the following characteristics, as they may require caution or dosage adjustment:

• Age: Older adults (65 years and older) due to increased risk of side effects; children under 6 years for OTC formulations.
• Comorbidities: Patients with liver disease, kidney impairment, asthma, prostatic enlargement (difficulty urinating), or persistent cough with excessive mucus.
• Physiological State: Pregnant or breastfeeding women, due to limited safety data and potential effects on the infant.

Official labeling defines who must not use the medicine (Contraindicated) and who must first seek medical guidance (Restricted Use), establishing a controlled eligibility framework.

Interactions with other medicines and products

Respira-D can interact with several medicinal products and substance categories, potentially leading to serious adverse effects or increased sedation. Patients must inform their healthcare provider of all prescription and over-the-counter medications and herbal supplements they are currently taking.

Contraindicated Combinations

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping MAOI therapy (e.g., phenelzine, isocarboxazid, tranylcypromine, selegiline), is strictly contraindicated. This combination carries a risk of severe reactions, including hypertensive crisis and significantly potentiated drug effects.
• Tricyclic Antidepressants (TCAs): Use with TCAs may also carry a risk of increased blood pressure or hypertensive crisis.

Clinically Significant Interactions

• Central Nervous System (CNS) Depressants: Avoid co-administration with other CNS depressants, including alcohol, opioids, certain antihistamines, antipsychotic agents, and anti-anxiety medications. Combining these substances can result in additive CNS depression, leading to excessive drowsiness, dizziness, and impaired mental and physical performance.
• Anticholinergic Drugs: Use with caution. Combining Respira-D with anticholinergic agents (e.g., some medications for irritable bowel syndrome or bladder control) may increase the risk of adverse effects, such as paralytic ileus.

Timing-based rules require a 14-day washout period after stopping MAOIs before initiating Respira-D therapy.

Respira-D functions via a dual-mechanism approach, involving the biological targets of its two active components: dextromethorphan and chlorpheniramine.

Dextromethorphan exhibits antitussive activity primarily within the central nervous system (CNS), specifically targeting the medullary cough center. It acts as an agonist at the sigma-1 receptor (sigma1), modulating neurotransmission within the cough reflex arc. The downstream cascade involves the suppression of afferent nerve impulse transmission to the cough-generating musculature, resulting in a systemic physiological consequence of reduced cough reflex sensitivity and frequency.

Chlorpheniramine is a competitive antagonist at the peripheral histamine H1 receptor (H1). By binding to the H1 receptor on target cells in the respiratory mucosa and vascular endothelium, it blocks the effect of endogenous histamine, a potent mediator released during immunological challenges. The molecular and cellular pathway involves the inhibition of histamine-induced H1 receptor signaling, which modulates microvascular permeability and glandular secretion. This action results in a system-level physiological modulation of reduced fluid transudation and diminished secretomotor activity in the upper respiratory tract.

How to Use Respira-D: Official Administration Guidelines

Respira-D, a combination of Chlorpheniramine and Dextromethorphan, is administered strictly according to official regulatory labeling to ensure proper use. This medicine is available in approved Oral dosage forms, including liquid solution/syrup and tablets.

Standard Dosing Regimens

Official labeling defines specific dosage and frequency constraints, emphasizing the principle to not exceed recommended dosage.

Population	Dosing Regimen (General Labeling)	Maximum Daily Exposure
Adults & Children 12 yrs and older	1 tablet or liquid equivalent (e.g., 20 mL of a standard solution) every 4 to 6 hours.	Not more than 4-6 doses in 24 hours (varies by formulation/strength)
Children 6 to < 12 yrs	Typically a reduced dose (e.g., 1/2 tablet or 10 mL of a standard liquid) every 4 to 6 hours.	Consult the specific product label; often restricted to a lower 24-hour maximum.
Children < 6 yrs	Do Not Use unless expressly directed by a healthcare professional.	-

Administration Requirements

• Frequency and Timing: Dosing is based on a fixed interval, to be taken every 4 to 6 hours as needed. The medication is intended only for a short-term course.
• Measurement: Liquid formulations must be measured using the enclosed or provided dosing device (cup or syringe); household spoons must not be used to ensure accurate administration.
• Intake Conditions: The medication may be taken by mouth with or without food. If the dosage form is an extended-release tablet, official instructions prohibit crushing, chewing, or breaking the tablet.
• Missed Dose: If a dose is missed, it should be skipped if it is close to the time of the next scheduled dose. Do not take two doses at the same time to compensate for a missed dose.

Research evidence / Overview of studies for Respira-D

1. Evidence for Use in Common Cold and Upper Respiratory Symptoms

This section summarizes the structure of available research for the combination's evaluation in common cold symptoms, including the types of randomized controlled trials (RCTs) and systematic reviews that assessed symptom patterns.

Study designs included randomized controlled trials (RCTs), systematic reviews, and meta-analyses. Research examined symptom variability over time. Studies were comparative, often assessing outcomes against an inactive control or single-ingredient cold therapies. Outcomes related to episodic or acute changes were measured, including objective and subjective cough frequency and change in Total Symptom Scores (TSS), which monitor physiological strain or stress.

Studies monitored measurements of symptoms in the observed populations over defined time intervals, typically spanning less than 7 days. Findings describe patterns observed in the studies, and evidence quality varies across studies. Systematic reviews noted that some trials measured differences in outcomes when compared to an inactive substance. Findings were mixed when systematically reviewing the effects of single agents or multi-agent combinations in the broader evidence landscape.

2. Evidence for Unproductive Cough Associated with Allergies

This section outlines the research base relevant to the evaluation of the combination for dry cough when it occurs alongside allergic rhinitis, detailing the kinds of post-marketing and observational studies that have been conducted.

Research explored short-term symptom patterns in conditions associated with acute or disruptive episodes, specifically non-productive cough co-occurring with allergic rhinitis. The evidence base includes open-label post-marketing surveillance (PMS) studies and data extrapolated from studies on the individual components. Research explored measurements of non-productive cough using assessment tools like the Cough Severity Score (CSS) over defined time intervals.

3. Scope of Long-Term Studies and Follow-up Data

The majority of available evidence is derived from studies monitoring responses over defined time intervals that are typically short. Consequently, long-term effects are not fully established. There is limited information for long-term outcomes or the durability of observed symptomatic patterns.

4. Evidence in Specific Age Groups

Research focused primarily on adult populations with common cold symptoms. Data for certain groups, particularly very young children, remain insufficient to establish the observed patterns. The data do not support extrapolation to other age ranges where specific, focused trials are lacking.

5. Summary of Research Gaps and Uncertainty

Key limitations include the fact that evidence quality varies across studies, and findings were mixed. Comparative evidence is lacking for the specific fixed-dose combination of only Chlorpheniramine and Dextromethorphan, as many research scenarios involved formulations with additional active ingredients. This research describes findings related to group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. DailyMed Monograph for Chlorpheniramine Maleate and Dextromethorphan Hydrobromide Oral Solution

Common questions about Respira-D (FAQ)

Q: Does this medication make you sleepy or affect your ability to drive?

Official product information indicates that this medicine may cause effects such as dizziness, drowsiness, or visual disturbances. Because of this, patients should be cautioned about operating machinery or driving a vehicle. This is why patients are advised to assess their individual response to the medication before engaging in complex activities.

---

Q: Can I take this medicine with alcohol?

Regulatory documents advise caution regarding the concomitant use of this medicine and alcohol. The combination may increase the risk of certain serious side effects, including profound sedation and respiratory depression. The official product information indicates that alcohol consumption should be avoided or limited.

---

Q: Is this medicine safe for me to use if I am pregnant or breastfeeding?

According to the official product information, this medicine is not generally recommended for use during pregnancy due to the potential for harm to the fetus. It is also currently unknown whether the medicine passes into breast milk. Any decision regarding use during pregnancy or while breastfeeding should be made after consulting the specific product label information and a healthcare professional.

---

Q: What is the correct way to store this medicine?

The medicine should be stored at controlled room temperature, typically between 20 C to 25 C. It must also be protected from light and moisture and kept securely in its original packaging. Storage directions also specify that the product must be kept out of the reach of children.

---

Q: Can I give this medicine to my 2-year-old child?

The approved indications and dosing instructions for Respira-D are for use in adults and pediatric patients aged 12 years and older. The safety and effectiveness of this medicine have not been established in children under the age of 12 years. The official labeling provides confirmation of the appropriate age group for use.

---

Q: What should I do if I miss a dose?

If a dose is missed, the regulatory directions indicate that the dose may be taken as soon as it is remembered. However, if it is nearly time for your next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Patients are cautioned not to take two doses at the same time to compensate for a missed dose.

How to Store and Dispose of Respira-D

Respira-D, an oral combination product, must be stored under specific environmental conditions defined in its official labeling to maintain its stability.

Storage Requirements

The medicine must be stored at controlled room temperature, typically below 25^circC (77^circF) or 30^circC (86^circF). It must be protected from heat, moisture, and direct light by storing it in a clean, dry place. The container must be kept tightly closed when not in use. It is explicitly mandated that the medicine must not be refrigerated or frozen.

Safety and Stability

For safety, Respira-D must always be stored out of the sight and reach of children and pets. The product must not be used after the expiry date printed on the packaging or if any visible signs of degradation, such as color change, are present.

Disposal Instructions

Unused or expired medicine must be disposed of properly in accordance with local regulatory requirements. Official guidance restricts discarding the product by flushing it down a toilet or pouring it into a drain. Instead, it should be disposed of via a drug take-back program or mixed with an undesirable substance before being placed in the household trash.